Compound hub · Retatrutide
Retatrutide study findings: what do the clinical trials show?
Retatrutide is an experimental compound still in clinical trials. In TRIUMPH-1, an 80-week Phase 3 trial of 2,339 adults without diabetes, average weight fell by up to 25.0% on retatrutide, against 3.9% on placebo. The developer funded the trial. It left out people with diabetes. On 14 September 2026 the TGA reported that neither it nor a similar overseas regulator has approved retatrutide. The results describe the trial people only.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
A scale gives you one number on one morning. A clinical trial has to do something harder. It counts that number across hundreds of people over many months. It sets them beside a group that got no active treatment. Most questions about retatrutide start with a single number from a headline. A number only means something with its trial attached.
This page is part of the retatrutide hub. It reports what published studies and trial registries say. The study model, the size, the funder and the limits sit beside each result. It never says what a compound does for a reader. The side-effect record has its own page.
Key facts
| Common name | retatrutide |
|---|---|
| Research code | LY3437943 |
| Developer and trial sponsor | Eli Lilly and Company |
| Phase 2 obesity trial | NCT04881760; 338 adults; 48 weeks; Jastreboff et al., NEJM, 2023 |
| Phase 2 result, highest arm | -24.2% average body-weight change at 48 weeks against -2.1% with placebo (338 adults with obesity; developer-funded; a group average that describes that trial only; Jastreboff et al., NEJM, 2023) |
| Phase 3 TRIUMPH-1 | NCT05929066; 2,339 adults without diabetes; 80 weeks; NEJM, 29 September 2026 |
| TRIUMPH-1 result | -17.6% to -25.0% across three retatrutide arms against -3.9% with placebo (2,339 adults without diabetes; developer-funded; group averages that describe that trial only; Jastreboff et al., NEJM, 2026) |
| Phase 3 TRIUMPH-2 | NCT05929079; 1,152 adults with obesity and type 2 diabetes; 80 weeks; The Lancet, 10 October 2026 |
| TRIUMPH-2 result | -11.9% to -18.8% across three retatrutide arms against -5.1% with placebo (1,152 adults with obesity and type 2 diabetes; developer-funded; group averages that describe that trial only; Bellido et al., The Lancet, 2026) |
| Retatrutide records on ClinicalTrials.gov | 34 (ClinicalTrials.gov search for retatrutide, 14 October 2026); 14 are Phase 3 |
| Records listing Australian sites | 6; one recruiting (NCT07165028) |
| Approval as of 14 October 2026 | Not approved by the TGA or a comparable international regulator (TGA safety alert, 14 September 2026) |
What are the real results from retatrutide trials?
Retatrutide trials recorded an average fall in body weight in every group studied. In the Phase 2 obesity trial of 338 adults, the highest group averaged −24.2% at 48 weeks, against −2.1% on placebo. In the Phase 3 TRIUMPH-1 trial of 2,339 adults without diabetes, the three retatrutide groups averaged −17.6% to −25.0% at 80 weeks, against −3.9% on placebo. In the Phase 3 TRIUMPH-2 trial, 1,152 adults with type 2 diabetes averaged −11.9% to −18.8%, against −5.1% on placebo. The developer funded all three trials. Each result applies only to the kind of people in that trial. None predicts one person's result.
Trials grow in steps. Phase 1 checks safety in a small group. Phase 2 tests effects in a few hundred people. Phase 3 tests in thousands. In the Phase 2 obesity trial, 83% of people in the highest group had lost at least 15% of body weight at 48 weeks, against 2% on placebo. That is an early-phase result from a trial the developer funded.
Other trials asked other questions. TRANSCEND-T2D-1 followed 537 adults with type 2 diabetes for 40 weeks. HbA1c is a blood test that shows average blood sugar over about three months. It fell 1.69 to 1.94 points across the retatrutide groups, against 0.81 on placebo. That result is for adults with type 2 diabetes in a trial the developer funded. The retatrutide research guide covers what the compound is.
A before-and-after photo is not a result. It has no comparison group and no measured starting point. It cannot separate one compound from everything else that changed in a person's life. Trials close those gaps by design. That is why this page quotes trials, registries, regulator documents and reviews, each with its source.

What have retatrutide trials measured in women?
Retatrutide trials have measured weight change in women. They have not measured effects on fertility, pregnancy or menopause. In the Phase 2 obesity trial, which the developer funded, a planned analysis at 48 weeks estimated an average weight change of −26.6% in women and −21.9% in men in the highest retatrutide group. Women on placebo averaged −2.6%. These figures come from Table S7 of the paper's supplementary appendix, which holds the extra tables published with it. They describe trial groups. They do not explain why the groups differed. They do not predict one person's result.
The figures for women and men come from a statistical model, not a simple average. The Phase 2 study guide explains the wider trial design.
Evidence limits
What do the retatrutide studies not show?
Five things stay open as of 14 October 2026. First, on 14 September 2026 the TGA reported that neither it nor a similar overseas regulator has approved retatrutide. So no approved label from those regulators lists its uses or risks. Second, Eli Lilly funded every retatrutide trial cited on this page. Third, we read the 2026 Phase 3 papers as abstracts, which are short summaries. So their full side-effect tables are not reported here. Fourth, the two registered head-to-head trials have no results posted. They compare retatrutide with tirzepatide and with semaglutide (NCT06662383 and NCT06260722). Fifth, the human results describe trial drug, not research-use material.
Abstracts leave out detail. The journal papers hold tables of side effects for each trial group. This page cannot quote what it did not read. Where a rate is missing below, the page says so and does not estimate it.
The trials also enrolled screened volunteers. TRIUMPH-1 excluded people with diabetes, a history of pancreatitis, or recent use of weight-loss drugs. So its averages describe that group. Two other Phase 3 trials, TRIUMPH-3 and TRIUMPH-4, are completed in the registry. They have no results posted (NCT05882045 and NCT05931367, checked 14 October 2026).
How quickly did weight change in retatrutide trials?
The trials report weight change over weeks and months. The three key papers checked on 14 October 2026 give no average change at four weeks. In the first human study, 45 healthy adults each had one exposure. A fall in body weight lasted up to day 43. In a 12-week Phase 1b trial of 72 adults with type 2 diabetes, the fall beyond placebo reached up to 8.96 kg in the highest group. In the Phase 2 obesity trial of 338 adults, the highest group averaged −17.5% at 24 weeks and −24.2% at 48 weeks. These results come from early, small or single trials.
In the Phase 2 trial, weight kept falling between 24 and 48 weeks in every retatrutide group. In the highest group it went from −17.5% to −24.2%. In the lowest it went from −7.2% to −8.7%. Those are group averages from one trial that the developer funded. The shape of the curve says more than any single week.
Some early signals came from interviews, not scales. An exit-interview study asked 40 adults with obesity from the Phase 2 trial. The developer funded it. Of 36 people on retatrutide, 31 said their eating habits had changed within the first 8 weeks. The authors note that the interviews happened once, at the end of the trial, so memories may be imperfect.
The papers checked on 14 October 2026 do not describe a typical first week. In the Phase 1b trial of 72 adults with type 2 diabetes, gut problems were the most often reported side effects over its 12 weeks. It was a small early-phase trial. The side-effect record sits on its own page.
Did every participant in retatrutide trials lose weight?
The published figures cannot say, because group results hide each person's result. In the Phase 2 obesity trial of 338 adults, 92% of the second-lowest group had lost at least 5% of body weight at 48 weeks. Also 60% had lost at least 15%. On placebo, 27% had lost at least 5%. Because 92% is not 100%, some people in that group lost less than 5%. That does not show that anyone gained weight or lost none. The trial was early-phase and the developer funded it. Its abstract gives no such figures for the lowest group. No paper read for this page explains why one person lost less than another.
Weight gain is a separate question. Weight increase is not on the ClinicalTrials.gov list of events reported by 5% or more of people in any group of the Phase 2 obesity trial. That list cannot show how many people gained weight (NCT04881760). The placebo group changed too, averaging −2.1% at 48 weeks.
The exit-interview study gives a human side to the averages. Of 36 people on retatrutide, 30 had weight loss as a goal. Of those 30, 76.7% said they reached it, and 3 described frustration with disappointing weight loss. These are self-reports, not measurements, from a study the developer funded. This page does not guess at causes for any one person's result.
What do studies show about retatrutide, fat loss and energy?
Studies measured fat loss directly. They did not measure energy 'burning'. A substudy of 189 adults with type 2 diabetes was funded by the developer. It measured body fat with DXA scans, a type of X-ray that tells fat apart from lean tissue. By week 36, total fat mass fell 23.2% in the highest group and 26.1% in the combined third-level groups. It fell 4.5% on placebo and 2.6% on dulaglutide. Only 103 people finished treatment with both scans. An imaging study of 98 adults started with liver fat of 10% or more. Liver fat fell 82.4% by week 24 in the highest group.
The liver study's authors included employees of the developer. It was one small study. The word 'burn' implies energy use, and the DXA substudy did not measure that. Its authors report that lean mass made up a similar share of the weight lost as with other obesity treatments. That comparison comes from the 103 people who finished treatment with both scans.
Energy use has a mouse result and a human trial with no published numbers yet. In obese mice, action at the glucagon receptor added a rise in energy use on top of the eating effect of the other two receptors. The abstract gives no animal count. A mouse result does not establish a human result. A human study of calorie intake and energy use, NCT06313528, finished on 26 August 2025 and has no results posted (checked 14 October 2026).
Energy as a feeling is a different measure. In the exit-interview study, 24 of 36 people on retatrutide reported changes in energy levels that they called improvements. These are self-reports, not a measured energy result. Fatigue was also a recorded side effect in the Phase 2 obesity trial. It was reported by 19 of 267 people on retatrutide and 3 of 70 on placebo.
What do studies show about retatrutide and alcohol?
No human study of retatrutide with alcohol turned up in the sources read for this page. A ClinicalTrials.gov search on 14 October 2026 found no registered retatrutide trial on alcohol use or alcohol interaction among its 34 records. The only retatrutide alcohol data found come from rats. A 2026 study in male and female rats gave one treatment of retatrutide, semaglutide or tirzepatide. Each made the animals less able to tell alcohol's effects apart. The abstract gives no animal count. A rat result does not establish a human result.
For the wider drug class, one randomised trial in people turned up. It enrolled 48 adults with alcohol use disorder. Semaglutide, not retatrutide, cut alcohol intake in a lab task, drinks per drinking day and craving over 9 weeks. It did not change average drinks per calendar day or the number of drinking days. The authors call this small trial first evidence that justifies larger trials.
The rat study and a 2023 paper on gastric emptying report no retatrutide findings on hangovers or getting drunk faster. Both were checked on 14 October 2026. Gastric emptying is the speed at which the stomach empties. The 2023 paper studied it for retatrutide but did not report an alcohol-absorption result.
Can retatrutide cause hair loss?
The records checked on 14 October 2026 give no retatrutide hair-loss rate. The posted side-effect tables of the two Phase 2 trials do not list hair loss. One trial had 338 adults with obesity (NCT04881760). The other had 281 adults with type 2 diabetes (NCT04867785). But those tables only show events reported by at least 5% of people in a group. So they cannot show how often hair loss happened. We read the Phase 3 papers as abstracts, which do not mention it. Labels for two other medicines, tirzepatide and semaglutide, record hair loss and link it to weight reduction. Those are figures for other medicines, not a retatrutide rate.
The US Zepbound label pools two placebo-controlled trials with 2,519 adults with obesity or overweight on tirzepatide. Hair loss was reported in 7.1% of women and 0.5% of men on tirzepatide, against 1.3% and 0% on placebo (DailyMed, 2 September 2026). The US Wegovy label reports hair loss in 3.3% on semaglutide, against 1% on placebo. It pools three trials of adults with obesity or overweight (2,116 on semaglutide and 1,261 on placebo) (DailyMed, 30 June 2026). A 2026 skin-care review lists alopecia, which is hair loss, among the skin side effects of the whole drug class. It is a narrative review. Its abstract gives no study count and no retatrutide rate.
Those are statements about other medicines and about the class. They are not a measured retatrutide rate, and this page does not guess one. The retatrutide side-effect numbers that exist are on the side-effects page.
What causes diarrhoea with retatrutide?
The trial records count diarrhoea but do not prove one cause. TRIUMPH-2 was a trial of 1,152 adults with type 2 diabetes, funded by the developer. Diarrhoea affected 27%, 34% and 34% of the three retatrutide groups, against 13% on placebo. In the Phase 2 obesity trial of 338 adults, the registry lists diarrhoea in 37 of 267 people on retatrutide (14%), against 8 of 70 on placebo (11%). That list only counts events reported by at least 5% of people in a group. A 2026 expert review of the drug class lists three suspected causes of gut side effects. They are slower stomach emptying, changed gut movement and rapid weight loss.
The review is a narrative expert review, not a trial. Its abstract gives no study count. It does not show these causes for retatrutide. A suspected cause is not a proven one. Gut side effects also differ from person to person, and the trials report group counts only.
The papers also describe how severe the gut events were. The Phase 2 obesity paper says they grew with the trial group level and were mostly mild to moderate in its 338 participants. The developer funded that trial. TRANSCEND-T2D-1 was a trial of 537 adults with type 2 diabetes. It says the events were generally mild to moderate and eased over time. The side-effects page sets out nausea, vomiting and constipation rates beside diarrhoea.
When were the first retatrutide trials registered and published?
The first retatrutide trial was posted on ClinicalTrials.gov on 15 February 2019. It was NCT03841630, a Phase 1 study that tested safety in people for the first time. The Phase 2 obesity trial, NCT04881760, was first posted on 11 May 2021 and started on 20 May 2021. Its paper appeared online in the New England Journal of Medicine on 26 June 2023. Its results were first posted on ClinicalTrials.gov on 13 September 2023. The Phase 2 trial in type 2 diabetes, NCT04867785, was published online in The Lancet on the same day as the obesity paper.
The year 2023 causes a common mix-up. That is when Phase 2 results reached print. It is not when human trials began. Phase 1 started on 13 March 2019. The first paper with human results appeared in 2022.
The Phase 2 paper, read in detail explains which end point was the main one and which were secondary. The comparison table below lists the registered trials that matter most, with their first-posted dates.
Which retatrutide Phase 3 trials are registered, and what have they reported?
ClinicalTrials.gov listed 34 retatrutide records on 14 October 2026. Of these, 14 are Phase 3, the large late-stage trials. A PubMed search the same day found journal results for three. TRANSCEND-T2D-1 was in The Lancet on 13 June 2026. TRIUMPH-1 was in the New England Journal of Medicine on 29 September 2026. TRIUMPH-2 was in The Lancet on 10 October 2026. TRIUMPH-3 and TRIUMPH-4 are completed but have no results posted. Eli Lilly is the lead sponsor of 32 of the 34 records.
TRIUMPH-1 included 574 people with knee osteoarthritis. In that subgroup, the WOMAC pain score changed by −3.2 to −3.6 in the retatrutide groups, against −1.9 on placebo. WOMAC is a 1 to 10 scale where higher means worse pain. The paper used a 'hybrid estimand', a method that handles events such as stopping treatment. We read this subgroup result from the abstract. It does not describe other participants.
Several Phase 3 trials are still running. TRIUMPH-5 (NCT06662383) compares retatrutide with tirzepatide in 800 adults. It lists its main completion as estimated for November 2026. TRIUMPH-6 (NCT06859268) tests weight maintenance and lists April 2028. Registry dates are plans, and they change.
Is there a retatrutide clinical trial in Australia, and who can join one?
Yes. Six retatrutide records on ClinicalTrials.gov list Australian sites. One of them, NCT07165028, was recruiting on 14 October 2026. That Phase 3 trial tests retatrutide and tirzepatide against placebo. It enrols adults with metabolic dysfunction-associated steatotic liver disease (MASLD), a build-up of fat in the liver, who are at risk of liver problems. Its Australian sites include Fiona Stanley Hospital in Murdoch and a second site in Osborne Park, Western Australia. The other five records are completed, or active and not recruiting. Each record sets its own entry rules. This page does not recruit.
A registry record lists who may take part and where the sites are. NCT07165028 needs liver fat of 8% or more and sets limits on liver stiffness. It excludes people with another liver disease, a body mass index under 25, or type 1 diabetes. It is a liver-outcomes trial, not a weight-loss trial.
The Australian New Zealand Clinical Trials Registry (ANZCTR) is the Australian registry. We could not complete a search there for this page. So a trial listed only on ANZCTR would not appear here. Retatrutide's approval and legal status in Australia covers the TGA position and the registry records in more detail.
Do these findings apply to research-use retatrutide?
No. The human trial results on this page come from trial drug given to enrolled participants under clinical trial conditions. The mouse and rat findings come from laboratory animals. Research-use reference material is a laboratory compound. Research material is not a medicine. It is not a substitute for one. It is not for human or animal use. No trial result here describes it. On 14 September 2026 the TGA reported that one product sold as retatrutide held undeclared semaglutide and no retatrutide. That finding is about that one sample (TGA safety alert, 14 September 2026).
Lab work uses reference material that comes with paperwork. This site's retatrutide reference material listing is freeze-dried stock for the lab.
Comparison
Registered retatrutide trials on ClinicalTrials.gov, checked 14 October 2026. Enrolment is the registry count. Dates are the registry's own. This table is a record list, not a ranking.
| Trial | Registry number | Participants | First posted | Status on 14 October 2026 |
|---|---|---|---|---|
| Phase 1, single exposure, healthy adults | NCT03841630 | 45 | 15 February 2019 | Completed 25 July 2019; Coskun et al., Cell Metabolism, 2022, report a Phase 1 first-in-human study |
| Phase 1b, type 2 diabetes, 12 weeks | NCT04143802 | 72 | 29 October 2019 | Completed 28 December 2020; Urva et al., The Lancet, 2022 |
| Phase 2, obesity, 48 weeks | NCT04881760 | 338 | 11 May 2021 | Completed 22 November 2022; Jastreboff et al., NEJM, 2023 |
| Phase 2, type 2 diabetes | NCT04867785 | 281 | 30 April 2021 | Completed 27 October 2022; Rosenstock et al., The Lancet, 2023 |
| TRIUMPH-1, obesity without diabetes, 80 weeks | NCT05929066 | 2,335 | 3 July 2023 | Completed 30 April 2026; Jastreboff et al., NEJM, 29 September 2026 |
| TRIUMPH-2, obesity with type 2 diabetes | NCT05929079 | 1,152 | 3 July 2023 | Completed 16 June 2026; Bellido et al., The Lancet, 10 October 2026 |
| TRIUMPH-3, obesity with cardiovascular disease | NCT05882045 | 1,946 | 31 May 2023 | Completed 14 May 2026; no results posted |
| TRIUMPH-4, obesity with knee osteoarthritis | NCT05931367 | 445 | 5 July 2023 | Completed 14 November 2025; no results posted |
| TRANSCEND-T2D-1, type 2 diabetes, 40 weeks | NCT06354660 | 537 | 9 April 2024 | Completed 20 February 2026; Bajaj et al., The Lancet, 13 June 2026 |
| TRIUMPH-5, retatrutide against tirzepatide | NCT06662383 | 800 | 28 October 2024 | Active, not recruiting; primary completion estimated November 2026 |
FAQ
Do retatrutide trial findings establish effects on fertility, pregnancy or menopause?
No. Retatrutide's obesity trial abstract and Supplementary Appendix, checked on 16 October 2026, report no fertility, pregnancy or menopause symptom outcomes (Jastreboff et al., NEJM, 2023). Pregnancy screening and breastfeeding exclusions are entry rules, not evidence for those groups. This finding is limited to those sources. It does not cover every retatrutide study.
Is retatrutide stronger than Mounjaro?
No head-to-head result was found in the sources checked on 14 October 2026. TRIUMPH-5 (NCT06662383, 800 adults) is the registered head-to-head trial of retatrutide against tirzepatide, the molecule in Mounjaro. Its primary completion is listed as estimated for November 2026. It had no results posted when ClinicalTrials.gov was checked on 14 October 2026. How retatrutide, Mounjaro and Ozempic differ sets out the separate records.
Has any study tested switching from tirzepatide to retatrutide?
The TRIUMPH-1 and TRIUMPH-5 registry records checked on 14 October 2026 do not describe a switch from tirzepatide to retatrutide. Both trials excluded people who had taken weight-loss drugs within 90 days before screening (ClinicalTrials.gov NCT05929066 and NCT06662383). TRIUMPH-5 compares the two molecules in separate groups. That is not a switch.
Who was excluded from retatrutide trials, and is there a label list?
The TGA reported on 14 September 2026 that neither it nor a similar overseas regulator has approved retatrutide. So this page found no approved list of people excluded from its use. Trial entry rules differ from a label. TRIUMPH-1 excluded diabetes, past pancreatitis, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and a weight change of more than 5 kg in the past 90 days (ClinicalTrials.gov NCT05929066). The expanded-access record excludes anyone with a medical contraindication (NCT07629401).
Is there an early-access record for retatrutide?
The developer has a United States expanded-access record, NCT07629401, with status Available, last updated 6 August 2026. It covers single-patient pre-approval access. It is for adults with a body mass index of 35 or more and two or more serious obesity-related complications who cannot join a trial. It states that availability depends on geography, product supply and eligibility. The record lists no Australian site (ClinicalTrials.gov, checked 14 October 2026).
Is retatrutide available in Australia?
Retatrutide is not approved in Australia. The TGA stated on 14 September 2026 that retatrutide is in human clinical trials. It said the TGA and any comparable regulator have not approved it. It also said a retatrutide product accessed outside a trial could be counterfeit (TGA safety alert, 14 September 2026). The legal status page sets out each record with its date.
Is retatrutide addictive?
None of the Coskun 2022, Urva 2022, Jastreboff 2023 and Windram 2026 papers, nor the NCT06313528 registry record, reports a human retatrutide outcome on dependence, withdrawal or abuse risk (checked 14 October 2026). A calorie-intake trial excluded people with a history of substance use disorder at entry (ClinicalTrials.gov NCT06313528). That is an entry rule, not a finding about the compound.
Who invented retatrutide?
Eli Lilly developed retatrutide. Lilly scientists wrote the first paper that describes it, with Tamer Coskun as first author (Coskun et al., Cell Metabolism, 2022). Lilly also sponsors the Phase 3 trials (ClinicalTrials.gov NCT05929066). The paper reports the compound's journey from discovery to a first human study.
How is retatrutide made?
A 2026 chemistry paper in Organic Letters states that making retatrutide relies mostly on solid-phase peptide synthesis. That method builds the peptide chain step by step on a solid support. The paper also reports a liquid-phase method as an alternative. It is a method paper, not a manufacturing record (Mao et al., Organic Letters, 2026).
More in this hub
- Retatrutide vs Mounjaro vs Ozempic: what's the difference?
- What is the difference between GLP-1 and GLP-3?
- Is retatrutide available in the USA? What the public record says
- How much does retatrutide cost? Is there an approved price?
- What does retatrutide do in the body? The three receptors in the papers
- How are people getting retatrutide? Trials, approval and research supply
- Who should not take retatrutide? What the trial exclusion lists say
- What makes a peptide company reputable? How to check a supplier's testing
- What is replacing tirzepatide? Weight-loss medicines in Phase 3 in 2026
- Retatrutide and type 2 diabetes: what the trials measured
- How long has retatrutide been studied?
- Retatrutide pharmacokinetics: what is the half-life?
- Retatrutide Phase 2 trial: what did the paper find?
- What is the molecular formula of retatrutide?
- NCT05882045: what is the TRIUMPH-3 retatrutide trial?
- NCT05929066: what is the TRIUMPH-1 retatrutide trial?
- Where does tirzepatide come from? Lilly's LY3298176
- SURPASS and SURMOUNT: what the tirzepatide trials measured
- Retatrutide in Australia: is it legal, approved or available yet?
- Retatrutide side effects: what trials and regulators have recorded
Citations
16 sourcesJastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
doi:10.1056/NEJMoa2301972Jastreboff AM et al. New England Journal of Medicine. 2026, online 29 September (TRIUMPH-1).
doi:10.1056/NEJMoa2604169Bellido V et al. The Lancet. 2026;408(10563):1455-1472.
doi:10.1016/S0140-6736(26)01861-1Bajaj HS et al. The Lancet. 2026;407(10546):2402-2413.
doi:10.1016/S0140-6736(26)00967-0Rosenstock J et al. The Lancet. 2023;402(10401):529-544.
doi:10.1016/S0140-6736(23)01053-XUrva S et al. The Lancet. 2022;400(10366):1869-1881.
doi:10.1016/S0140-6736(22)02033-5Coskun T et al. Cell Metabolism. 2022;34(9):1234-1247.e9.
doi:10.1016/j.cmet.2022.07.013Coskun T et al. The Lancet Diabetes & Endocrinology. 2025;13(8):674-684.
doi:10.1016/S2213-8587(25)00092-0Sanyal AJ et al. Nature Medicine. 2024;30(7):2037-2048.
doi:10.1038/s41591-024-03018-2Goetz IA et al. Obesity Pillars. 2025;16:100220.
doi:10.1016/j.obpill.2025.100220Windram M et al. Psychopharmacology. 2026;243(5):1185-1197.
doi:10.1007/s00213-025-06854-3Hendershot CS et al. JAMA Psychiatry. 2025;82(4):395-405.
doi:10.1001/jamapsychiatry.2024.4789Urva S et al. Diabetes, Obesity and Metabolism. 2023;25(9):2784-2788.
doi:10.1111/dom.15167Singhani V et al. Nutrition in Clinical Practice. 2026;41(5):1318-1333.
doi:10.1002/ncp.70180Narla S et al. Clinics in Dermatology. 2026, online 6 August.
doi:10.1016/j.clindermatol.2026.07.030Mao CY et al. Organic Letters. 2026;28(23):7486-7490.
doi:10.1021/acs.orglett.6c02001
Continue
Retatrutide reference materialResearch use only, not for human or animal use.
Read the retatrutide research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
